Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients

Journal of Chemotherapy

Volumn 11, Issue 4, 1999, Pages 301-305

  Oliverio, Giovanni ^a,c   Canuti, D ^b   Tononi, A ^a   Scarpellini, M ^a   Panzini, I ^b   Galli, I ^a   Ravaioli, A ^a  

^a Infermi Hospital   (Italy)

^b ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^c Ospedale Infermi   (Italy)

Author keywords

Ovarian cancer; Paclitaxel; Second line therapy; Taxol ; Toxicity

Indexed keywords

PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; QUALITY OF LIFE; TREATMENT OUTCOME; VOMITING;

EID: 0032815483     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.4.301     Document Type: Article

References (19)

1. Boring CC, Squires TS, Tong T. Cancer statistics, 1991. Cancer J Clin 1991; 41: 19-52.
2. Parkin DM, Laarke E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988; 41: 184-197.
3. Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329: 1550-1559.
4. Lorigan PC, Crosby T, Coleman RE. Current drug treatment guidelines for epithelial ovarian cancer. Drugs 1996; 51: 571-584.
5. Neijt JP, Ten Bokkel Huinink W, van Der Burg M et al. Long term survival in ovarian cancer. Eur J Cancer 1991; 27:1367-1372.
6. Ozols RF. Treatment of ovarian cancer: current status. Semin Oncol 1994; 21:1-9.
7. Thigpen JT, Blessing JA, Vance RB, Lambuth BW. Chemotherapy in ovarian carcinoma: present role and future prospects. Semin Oncol 1989; 16: 58-65.
8. Ozols RF, Scwartz PE, Eifel PS. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. In: De Vita VT, Hellman S, Rosenberg SA. Cancer. Principles and Practice of Oncology. V eds. Philadelphia, PA, Lippincott, 1997: 1502-1539.
9. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique anti-neoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-279.
10. Sarosy G, Kohn E, Stone DA, et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10: 1165-1170.
11. Einzig AL, Wiernik PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1993; 10: 1748-1753.
12. Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum refractory ovarian cancer. Results from the first 1,000 patients registered to National Cancer Institute treatment referral center 9103. J Clin Oncol 1993; 11: 2405-2410.
13. Thigpen T, Blessing J, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynaecologic Oncology Group study. J Clin Oncol 1994; 12: 1748-1753.
14. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-2666.
15. Kris MG, O'Connell JP, Gralla RJ. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986; 70: 605-607.
16. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994; 5: 495-505.
17. World Health Organization: WHO handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva, Switzerland, World Health Organization, 1979.
18. Pectasides D, Papadopoulou M, Varthalitis J, et al. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study. Oncology 1998; 55(3): 228-34.
19. Philips KA, Friedlander M, Olver 1 et al. Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer. Aust N Z J Med 1995; 25 (4): 337-43.